Quantitative TCR:pMHC dissociation rate assessment by NTAmers reveals antimelanoma T cell repertoires enriched for high functional competence

Journal of Immunology

Volumn 195, Issue 1, 2015, Pages 356-366

  Gannon, Philippe O ^a   Wieckowski, Sébastien ^a,c   Baumgaertner, Petra ^b   Hebeisen, Michaël ^a   Allard, Mathilde ^a   Speiser, Daniel E ^a,b   Rufer, Nathalie ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CPG OLIGODEOXYNUCLEOTIDE; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELAN A; T LYMPHOCYTE RECEPTOR; CANCER VACCINE; HLA A ANTIGEN; LYMPHOCYTE ANTIGEN RECEPTOR; ORGANOMETALLIC COMPOUND; PEPTIDE; PROTEIN BINDING; TUMOR ANTIGEN;

ANTIGEN BINDING; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CALCIUM MOBILIZATION; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DISSOCIATION; HUMAN; HUMAN CELL; LOW DRUG DOSE; LYMPHOCYTE CLONE; LYMPHOCYTE DIFFERENTIATION; METASTATIC MELANOMA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; CANCER STAGING; CELL CLONE; CELL DIFFERENTIATION; CHEMISTRY; CLINICAL TRIAL; CYTOLOGY; CYTOTOXICITY; IMMUNIZATION; IMMUNOLOGY; KINETICS; MELANOMA; METASTASIS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; PROSPECTIVE STUDY; SKIN NEOPLASMS;

ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CLONE CELLS; CYTOTOXICITY, IMMUNOLOGIC; HLA-A ANTIGENS; HUMANS; IMMUNIZATION; KINETICS; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOMETALLIC COMPOUNDS; PEPTIDES; PROSPECTIVE STUDIES; PROTEIN BINDING; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; SKIN NEOPLASMS;

EID: 84932159335     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1403145     Document Type: Article

References (58)

1. Lanzavecchia, A., and F. Sallusto. 2002. Progressive differentiation and selection of the fittest in the immune response. Nat. Rev. Immunol. 2: 982-987.
2. Stone, J. D., and D. M. Kranz. 2013. Role of T cell receptor affinity in the efficacy and specificity of adoptive T cell therapies. Front. Immunol. 4: 244.
3. Stone, J. D., A. S. Chervin, and D. M. Kranz. 2009. T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology 126: 165-176.
4. Aleksic, M., N. Liddy, P. E. Molloy, N. Pumphrey, A. Vuidepot, K.-M. Chang, and B. K. Jakobsen. 2012. Different affinity windows for virus and cancerspecific T-cell receptors: implications for therapeutic strategies. Eur. J. Immunol. 42: 3174-3179.
5. Restifo, N. P., M. E. Dudley, and S. A. Rosenberg. 2012. Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12: 269-281.
6. Rosenberg, S. A., J. C. Yang, R. M. Sherry, U. S. Kammula, M. S. Hughes, G. Q. Phan, D. E. Citrin, N. P. Restifo, P. F. Robbins, J. R. Wunderlich, et al. 2011. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17: 4550-4557.
7. Radvanyi, L. G., C. Bernatchez, M. Zhang, P. S. Fox, P. Miller, J. Chacon, R. Wu, G. Lizeé, S. Mahoney, G. Alvarado, et al. 2012. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 18: 6758-6770.
8. Pilon-Thomas, S., L. Kuhn, S. Ellwanger, W. Janssen, E. Royster, S. Marzban, R. Kudchadkar, J. Zager, G. Gibney, V. K. Sondak, et al. 2012. Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma. J. Immunother. 35: 615-620.
9. Besser, M. J., R. Shapira-Frommer, A. J. Treves, D. Zippel, O. Itzhaki, L. Hershkovitz, D. Levy, A. Kubi, E. Hovav, N. Chermoshniuk, et al. 2010. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 16: 2646-2655.
10. Moran, A. E., and K. A. Hogquist. 2012. T-cell receptor affinity in thymic development. Immunology 135: 261-267.
11. Gronski, M. A., J. M. Boulter, D. Moskophidis, L. T. Nguyen, K. Holmberg, A. R. Elford, E. K. Deenick, H. O. Kim, J. M. Penninger, B. Odermatt, et al. 2004. TCR affinity and negative regulation limit autoimmunity. Nat. Med. 10: 1234-1239.
12. Li, J., O. Vandal, and D. B. Sant'Angelo. 2011. TCR affinity for self-ligands influences the development and function of encephalitogenic T cells. PLoS One 6: e17702.
13. Bettini, M., L. Blanchfield, A. Castellaw, Q. Zhang, M. Nakayama, M. P. Smeltzer, H. Zhang, K. A. Hogquist, B. D. Evavold, and D. A. A. Vignali. 2014. TCR affinity and tolerance mechanisms converge to shape T cell diabetogenic potential. J. Immunol. 193: 571-579.
14. Lever, M., P. K. Maini, P. A. van der Merwe, and O. Dushek. 2014. Phenotypic models of T cell activation. Nat. Rev. Immunol. 14: 619-629.
15. Schmidt, J., D. Dojcinovic, P. Guillaume, and I. Luescher. 2013. Analysis, isolation, and activation of antigen-specific CD4(+) and CD8(+) T cells by soluble MHC-peptide complexes. Front. Immunol. 4: 218.
16. Hombrink, P., Y. Raz, M. G. D. Kester, R. de Boer, B. Wei?brich, P. A. von dem Borne, D. H. Busch, T. N. M. Schumacher, J. H. F. Falkenburg, and M. H. M. Heemskerk. 2013. Mixed functional characteristics correlating with TCR-ligand koff-rate of MHC-tetramer reactive T cells within the naive T-cell repertoire. Eur. J. Immunol. 43: 3038-3050.
17. Zhu, C., N. Jiang, J. Huang, V. I. Zarnitsyna, and B. D. Evavold. 2013. Insights from in situ analysis of TCR-pMHC recognition: response of an interaction network. Immunol. Rev. 251: 49-64.
18. Schmidt, J., P. Guillaume, M. Irving, P. Baumgaertner, D. Speiser, and I. F. Luescher. 2011. Reversible major histocompatibility complex I-peptide multimers containing Ni(2+)-nitrilotriacetic acid peptides and histidine tags improve analysis and sorting of CD8(+) T cells. J. Biol. Chem. 286: 41723-41735.
19. Nauerth, M., B. Weissbrich, R. Knall, T. Franz, G. Dössinger, J. Bet, P. J. Paszkiewicz, L. Pfeifer, M. Bunse, W. Uckert, et al. 2013. TCR-ligand koff rate correlates with the protective capacity of antigen-specific CD8+ T cells for adoptive transfer. Sci. Transl. Med. 5: 192ra87.
20. Hebeisen, M., J. Schmidt, P. Guillaume, P. Baumgaertner, D. E. Speiser, I. Luescher, and N. Rufer. 2015. Identification of rare high avidity, tumor reactive CD8+ T cells by monomeric TCR-ligand off-rates measurements on living cells. Cancer Res. DOI: 10.1158/0008-5472.CAN-14-3516.
21. Speiser, D. E., D. Liénard, N. Rufer, V. Rubio-Godoy, D. Rimoldi, F. Lejeune, A. M. Krieg, J.-C. Cerottini, and P. Romero. 2005. Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115: 739-746.
22. Speiser, D. E., P. Baumgaertner, V. Voelter, E. Deve?vre, C. Barbey, N. Rufer, and P. Romero. 2008. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc. Natl. Acad. Sci. USA 105: 3849-3854.
23. Speiser, D. E., S. Wieckowski, B. Gupta, E. M. Iancu, P. Baumgaertner, L. Baitsch, O. Michielin, P. Romero, and N. Rufer. 2011. Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes. Proc. Natl. Acad. Sci. USA 108: 15318-15323.
24. Gupta, B., E. M. Iancu, P. O. Gannon, S. Wieckowski, L. Baitsch, D. E. Speiser, and N. Rufer. 2012. Simultaneous coexpression of memory-related and effectorrelated genes by individual human CD8 T cells depends on antigen specificity and differentiation. J. Immunother. 35: 488-501.
25. Valmori, D., J. F. Fonteneau, C. M. Lizana, N. Gervois, D. Liénard, D. Rimoldi, V. Jongeneel, F. Jotereau, J. C. Cerottini, and P. Romero. 1998. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol. 160: 1750-1758.
26. Britten, C. M., S. Janetzki, S. H. van der Burg, C. Huber, M. Kalos, H. I. Levitsky, H. T. Maecker, C. J. M. Melief, J. O'Donnell-Tormey, K. Odunsi, et al. 2011. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol. Immunother. 60: 15-22.
27. Britten, C. M., S. Janetzki, L. H. Butterfield, G. Ferrari, C. Gouttefangeas, C. Huber, M. Kalos, H. I. Levitsky, H. T. Maecker, C. J. M. Melief, et al. 2012. T cell assays and MIATA: the essential minimum for maximum impact. Immunity 37: 1-2.
28. Wieckowski, S., P. Baumgaertner, P. Corthesy, V. Voelter, P. Romero, D. E. Speiser, and N. Rufer. 2009. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J. Immunol. 183: 5397-5406.
29. Lefranc, M. P. 2001. Nomenclature of the human T cell receptor genes. Curr. Protoc. Immunol. Appendix 1: Appendix 1O.
30. Hebeisen, M., L. Baitsch, D. Presotto, P. Baumgaertner, P. Romero, O. Michielin, D. E. Speiser, and N. Rufer. 2013. SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J. Clin. Invest. 123: 1044-1056.
31. Baumgaertner, P., C. Jandus, J.-P. Rivals, L. Derré, T. Lövgren, L. Baitsch, P. Guillaume, I. F. Luescher, G. Berthod, M. Matter, et al. 2012. Vaccinationinduced functional competence of circulating human tumor-specific CD8 T-cells. Int. J. Cancer 130: 2607-2617.
32. Speiser, D. E., P. Baumgaertner, C. Barbey, V. Rubio-Godoy, A. Moulin, P. Corthesy, E. Deve?vre, P.-Y. Dietrich, D. Rimoldi, D. Liénard, et al. 2006. A novel approach to characterize clonality and differentiation of human melanomaspecific T cell responses: spontaneous priming and efficient boosting by vaccination. J. Immunol. 177: 1338-1348.
33. Alexander-Miller, M. A., G. R. Leggatt, and J. A. Berzofsky. 1996. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA 93: 4102-4107.
34. Zeh, H. J., III, D. Perry-Lalley, M. E. Dudley, S. A. Rosenberg, and J. C. Yang. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162: 989-994.
35. Bos, R., K. L. Marquardt, J. Cheung, and L. A. Sherman. 2012. Functional differences between low- and high-affinity CD8(+) T cells in the tumor environment. Oncoimmunology 1: 1239-1247.
36. Dutoit, V., V. Rubio-Godoy, P. Y. Dietrich, A. L. Quiqueres, V. Schnuriger, D. Rimoldi, D. Liénard, D. Speiser, P. Guillaume, P. Batard, et al. 2001. Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity. Cancer Res. 61: 5850-5856.
37. Schmid, D. A., M. B. Irving, V. Posevitz, M. Hebeisen, A. Posevitz-Fejfar, J.-C. F. Sarria, R. Gomez-Eerland, M. Thome, T. N. M. Schumacher, P. Romero, et al. 2010. Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J. Immunol. 184: 4936-4946.
38. Cole, D. K., E. S. J. Edwards, K. K. Wynn, M. Clement, J. J. Miles, K. Ladell, J. Ekeruche, E. Gostick, K. J. Adams, A. Skowera, et al. 2010. Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition. J. Immunol. 185: 2600-2610.
39. Huang, J., V. I. Zarnitsyna, B. Liu, L. J. Edwards, N. Jiang, B. D. Evavold, and C. Zhu. 2010. The kinetics of two-dimensional TCR and pMHC interactions determine T-cell responsiveness. Nature 464: 932-936.
40. Liu, B., S. Zhong, K. Malecek, L. A. Johnson, S. A. Rosenberg, C. Zhu, and M. Krogsgaard. 2014. 2D TCR-pMHC-CD8 kinetics determines T-cell responses in a self-antigen-specific TCR system. Eur. J. Immunol. 44: 239-250.
41. Wang, X. L., and J. D. Altman. 2003. Caveats in the design of MHC class I tetramer/antigen-specific T lymphocytes dissociation assays. J. Immunol. Methods 280: 25-35.
42. Barbey, C., P. Baumgaertner, E. Deve?vre, V. Rubio-Godoy, L. Derré, G. Bricard, P. Guillaume, I. F. Luescher, D. Liénard, J.-C. Cerottini, et al. 2007. IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells. J. Immunol. 178: 3566-3574.
43. Busch, D. H., and E. G. Pamer. 1999. T cell affinity maturation by selective expansion during infection. J. Exp. Med. 189: 701-710.
44. Malherbe, L., C. Hausl, L. Teyton, and M. G. McHeyzer-Williams. 2004. Clonal selection of helper T cells is determined by an affinity threshold with no further skewing of TCR binding properties. Immunity 21: 669-679.
45. Savage, P. A., J. J. Boniface, and M. M. Davis. 1999. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity 10: 485-492.
46. Zehn, D., S. Y. Lee, and M. J. Bevan. 2009. Complete but curtailed T-cell response to very low-affinity antigen. Nature 458: 211-214.
47. Baumgartner, C. K., and L. P. Malherbe. 2011. Antigen-driven T-cell repertoire selection during adaptive immune responses. Immunol. Cell Biol. 89: 54-59.
48. McMahan, R. H., J. A. McWilliams, K. R. Jordan, S. W. Dow, D. B. Wilson, and J. E. Slansky. 2006. Relating TCR-peptide-MHC affinity to immunogenicity for the design of tumor vaccines. J. Clin. Invest. 116: 2543-2551.
49. Kim, M., H.-B. Moon, K. Kim, and K.-Y. Lee. 2006. Antigen dose governs the shaping of CTL repertoires in vitro and in vivo. Int. Immunol. 18: 435-444.
50. Rees, W., J. Bender, T. K. Teague, R. M. Kedl, F. Crawford, P. Marrack, and J. Kappler. 1999. An inverse relationship between T cell receptor affinity and antigen dose during CD4(+) T cell responses in vivo and in vitro. Proc. Natl. Acad. Sci. USA 96: 9781-9786.
51. Lövgren, T., P. Baumgaertner, S. Wieckowski, E. Deve?vre, P. Guillaume, I. Luescher, N. Rufer, and D. E. Speiser. 2012. Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide dose. Cancer Immunol. Immunother. 61: 817-826.
52. King, C. G., S. Koehli, B. Hausmann, M. Schmaler, D. Zehn, and E. Palmer. 2012. T cell affinity regulates asymmetric division, effector cell differentiation, and tissue pathology. Immunity 37: 709-720.
53. Holler, P. D., and D. M. Kranz. 2003. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 18: 255-264.
54. Chervin, A. S., J. D. Stone, P. D. Holler, A. Bai, J. Chen, H. N. Eisen, and D. M. Kranz. 2009. The impact of TCR-binding properties and antigen presentation format on T cell responsiveness. J. Immunol. 183: 1166-1178.
55. Irving, M., V. Zoete, M. Hebeisen, D. Schmid, P. Baumgärtner, P. Guillaume, P. Romero, D. Speiser, I. Luescher, N. Rufer, and O. Michielin. 2012. Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J. Biol. Chem. 287: 23068-23078.
56. Zhong, S., K. Malecek, L. A. Johnson, Z. Yu, E. Vega-Saenz de Miera, F. Darvishian, K. McGary, K. Huang, J. Boyer, E. Corse, et al. 2013. T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proc. Natl. Acad. Sci. USA 110: 6973-6978.
57. Tian, S., R. Maile, E. J. Collins, and J. A. Frelinger. 2007. CD8+ T cell activation is governed by TCR-peptide/MHC affinity, not dissociation rate. J. Immunol. 179: 2952-2960.
58. Corse, E., R. A. Gottschalk, M. Krogsgaard, and J. P. Allison. 2010. Attenuated T cell responses to a high-potency ligand in vivo. PLoS Biol. 8: e1000481.